Clinical trials: Dementia Disorders
Dementia, Alzheimer Disease
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
The purpose of the study is to compare the risk of dementia in participants diagnosed with rheumatoid arthritis (RA) exposed to anti-tumor necrosis factor (TNF) therapy versus those exposed to methotrexate.
- Trial name
- NCT04571697
- Testing
- Methotrexate, Anti-TNF
- Where
- United States
- Volunteers
- 34,647 people
- Sponsor
- Janssen Research & Development, LLC
Mild Cognitive Impairment, Alzheimer's Disease(AD)
Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease
This study is a multicenter, randomized, double-blind, parallel-group, prospective confirmatory clinical trial designed to evaluate whether the Neuclare medical device can temporarily improve executive function (planning and…
- Trial name
- NCT07239310
- Testing
- Participants receive Neuclare Device while continuing their cognitive medication
- Where
- 7 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- Deepsonbio
Alzheimer Disease
Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production
Phase 1, Single-center, Open-label Study, Healthy Adult Male Subjects. Part 1:Single-dose, Placebo-controlled, 3-Way Crossover PK Study Part 2: Single dose 2-way comparator PK Study
- Trial name
- NCT03971123
- Testing
- Tricaprilin
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer's Disease
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
This is a single centre, 2 part study in older subjects. Part 1 (Pharmacokinetic [PK] Assessment) is a double blind, randomized, placebo-controlled 4-period crossover study investigating the PK profile of four different doses of…
- Trial name
- NCT01702480
- Testing
- GSK2981710
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
Metabolism, Alzheimer's Disease
Drug Interaction Study Between AZD3480 and Cytochrome P450
The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.
- Trial name
- Cocktail (NCT00692510)
- Testing
- AZD3480, Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, Alzheimer Disease
First in Human Study for Safety and Tolerability of AL003.
This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT03822208
- Testing
- AL003, Saline Solution
- Where
- 6 sites in United States, Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alector Inc.
Dementia Alzheimer's Type
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Primary Objective: To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on…
- Trial name
- NCT01266525
- Testing
- SAR110894, Donepezil
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 291 people
- Sponsor
- Sanofi
Alzheimer Disease
Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the optimal dose(s) to be used in…
- Trial name
- Sirocco (NCT00501111)
- Testing
- AZD3480, Donepezil
- Where
- 70 sites in Austria, Belgium and 8 more
- Volunteers
- 659 people
- Sponsor
- AstraZeneca
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, MCI
Validation Study of a New Digital Treatment Test
Oculomotor behavior and cognitive processing of visual information are intimately connected. AD patients show ocular movement problems.
- Trial name
- NCT04897464
- Testing
- BGaze therapy Alzheimer
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Braingaze
Healthy
A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants
The purpose of this study is to determine pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and the relative-bioavailability (the extent to which a drug or other substance becomes…
- Trial name
- NCT02260700
- Testing
- JNJ-54861911 (Treatment A), JNJ-54861911 (Treatment B), JNJ-54861911 (Treatment C)
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Huntington Disease
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
- Trial name
- NCT00146211
- Testing
- Ethyl-EPA (Miraxion™)
- Where
- 41 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Amarin Neuroscience Ltd
Alzheimer's Disease
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological assessment.
- Trial name
- NCT01447719
- Testing
- florbetapir F 18
- Where
- 22 sites in United States
- Volunteers
- 110 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Alzheimer Disease
Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease
The long-term safety and efficacy of galantamine (12 mg bid) will be documented during a one year open-label treatment in subjects with Alzheimer's Disease who completed the GAL-INT-8 trial (up to 400 eligible patients).
- Trial name
- NCT00304629
- Testing
- galantamine
- Volunteers
- 241 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Huntington Disease
Study of WVE-003 in Patients With Huntington's Disease
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who…
- Trial name
- NCT05032196
- Testing
- SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003
- Where
- 23 sites in Australia, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Wave Life Sciences USA, Inc.
Prion Disease
A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)
This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD). In PrD, the prion protein folds into an abnormal shape.
- Trial name
- NCT07832370
- Testing
- ALN-6457
- Volunteers
- 60 people
- Sponsor
- Regeneron Pharmaceuticals
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.
- Trial name
- NCT01421056
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 6 sites in United States, Italy
- Volunteers
- 74 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in patients with mild to moderate Alzheimer's…
- Trial name
- NCT03316898
- Testing
- AGN-242071, Donepezil, Memantine
- Where
- 6 sites in United States
- Sponsor
- Allergan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.